MEDICINA INTERNA

Artículos

Agud Fernández M, López López F, Díaz Pedroche C, Gómez Martín C. Concurrent inflammatory bowel disease and gastrointestinal stromal tumor. Gastroenterol Hepatol. 2018;41(5):310-1

Almorza T, Herrera Juárez M, Lalueza A. Spontaneous mediastinitis with multiple esophageal abscess in the esophagus. Respir Med Case Rep. 2018;25:196-8

Brito Zerón P, Kostov B, Moral Moral P, Martínez Zapico A, Díaz Pedroche C, Fraile G, et al. Prognostic factors of death in 151 adults with hemophagocytic syndrome: Etiopathogenically driven analysis. Mayo Clin Proc Innov Qual Outcomes. 2018;2(3):267-76.

Carril Ajuria L, Jiménez Aguilar E, Gómez Martín C, Díaz Pedroche C. An unsuspected complication with immune checkpoint blockade: a case report. J Med Case Rep. 2018;12(1):246

De Sautu de Borbón EC, Morales Conejo M, Guerra Vales JM. Prevalence of risk factors for the development of avascular hip necrosis in a third-level hospital. Reumatol Clin. 2018;14(2):122–3 [PubMed]

Drawz PE, Brown R, De Nicola L, Fujii N, Gabbai FB, Gassman J, et al. Variations in 24-hour BP profiles in cohorts of patients with kidney disease around the world: The I-DARE Study. Clin J Am Soc Nephrol. 2018;13(9):1348-57

Escolà Vergé L, Rodríguez Pardo D, Lora Tamayo J, Morata L, Murillo O, Vilchez H, et al. Candida periprosthetic joint infection: A rare and difficult-to-treat infection. J Infect. 2018;77(2):151-7 [PubMed]

García Villa A, Cabañuz C. Cutaneous hyperpigmentation in vitamine B12 deficiency. Rev Clin Esp. 2018;218(2):108-9 [PubMed]

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018 22;392(10152):1036-46

Gómez Cuervo C, Díaz Pedroche C, Pérez Jacoiste Asín MA, Lalueza A, Del Pozo R, Díaz-Simón R, et al. Impact of functional status on 6-month mortality in elderly patients with acute venous thromboembolism: results from a prospective cohort. J Thromb Thrombolysis. 2018;46(3):325-31

Luengo G, Lora Tamayo J, Paredes D, Muñoz Gallego I, Díaz A, Delgado E. Daptomycin plus fosfomycin as salvage therapy in a difficult-to-treat total femoral replacement infection. J Bone Jt Infect. 2018;3(4):207-11

Morales E, Alonso M, Sarmiento B, Morales M. LCAT deficiency as a cause of proteinuria and corneal opacification. BMJ Case Rep. 2018;2018 [PubMed]

Pérez López J, Moltó Abad M, Muñoz Delgado C, Morales Conejo M, Ceberio Hualde L, Del Toro M. Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature. Mol Genet Metab. 2018;124(3):216-27

Prieto Barrios M, Aragón Miguel R, Tarragó Asensio D, Lalueza A, Zarco Olivo C. Human herpesvirus 8-associated inflammatory cytokine syndrome. JAMA Dermatol. 2018;154(2):228–30 [PubMed]

Recio R, Villa J, Viedma E, Ángeles Orellana M, Lora Tamayo J, Chaves F. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: facing the perfect storm. Int J Antimicrob Agents. 2018;52(2):172–9 [PubMed]

Rodríguez López C, Ayuso García B, Moreno García S. Hypophonia as a sign of thalamus lesion: a case report. Int J Neurosci. 2018;128(1):100-1 [PubMed]

Ruiz Artacho P, Trujillo Santos J, López Jiménez L, Font C, Díaz Pedroche MDC, Sánchez Muñoz-Torrero JF, et al; RIETE Investigators . Clinical characteristics and outcomes of patients with lung cancer and venous thromboembolism. TH Open. 2018;2(2):e210-e217

Wouthuyzen-Bakker M, Lora-Tamayo J, Senneville E, Scarbourough M, Ferry T, Uçkay I, et al. Erysipelas or cellulitis with a prosthetic joint in situ. J Bone Jt Infect. 2018;3(4):222–5

Unidad de Enfermedades Infecciosas

Aguado JM, Silva JT, Fernández Ruiz M, Cordero E, Fortún J, Gudiol C, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev (Orlando). 2018;32(1):36–57 [PubMed]

Aguilar Company J, Fernández Ruiz M, García Campelo R, Garrido Castro AC, Ruiz Camps I. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biologic therapies: an infectious diseases perspective-cell surface receptors and associated signaling pathways. Clin Microbiol Infect. 2018;24 Suppl 2:S41-52 [PubMed]

Baddley JW, Cantini F, Goletti D, Gómez Reino JJ, Mylonakis E, San Juan R, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumour necrosis factor-α agents). Clin Microbiol Infect. 2018;24 Suppl 2:S10-20 [PubMed]

Clemente WT, Mourão PHO, Aguado JM. Current approaches to visceral leishmaniasis treatment in solid organ transplant recipients. Expert Rev Anti Infect Ther. 2018;16(5):391-7 [PubMed]

Clemente WT, Mourão PHO, López Medrano F, Schwartz BS, García Donoso C, Torre Cisneros J. Visceral and cutaneous leishmaniasis recommendations for solid organ transplant recipients and donors. Transplantation. 2018;102(2S Suppl 2):S8-15 [PubMed]

Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, López Vélez R, et al. Recommendations for management of endemic diseases and travel medicine in solid-organ transplant recipients and donors: Latin America. Transplantation. 2018;102(2):193-208 [PubMed]

Coussement J, Maggiore U, Manuel O, Scemla A, López Medrano F, Nagler EV, et al. Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. Nephrol Dial Transplant. 2018;33(9):1661-8  [PubMed]

Fernández Hidalgo N, Ribera A, Larrosa MN, Viedma E, Origüen J, De Alarcón A, et al. Impact of Staphylococcus aureus phenotype and genotype on the clinical characteristics and outcome of infective endocarditis. A multicentre, longitudinal, prospective, observational study. Clin Microbiol Infect. 2018;24(9):985–91

Fernández Ruiz M, Aguado JM. Risk of infection associated with anti-TNF-α therapy. Expert Rev Anti Infect Ther. 2018;16(12):939-56

Fernández Ruiz M, Corbella L, Morales Cartagena A, González E, Polanco N, Ruiz Merlo T, et al. Vitamin D deficiency and infection risk in kidney transplant recipients: a single-center cohort study. Transpl Infect Dis. 2018;e12988

Fernández Ruiz M, Meije Y, Manuel O, Akan H, Carratalà J, Aguado JM, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clin Microbiol Infect. 2018;24(Suppl 2):S2–9 [PubMed]

Fernández Ruiz M, Origüen J, Lora D, López Medrano F, González E, Polanco N, et al. Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study. Transpl Int. 2018;31(2):187–97 [PubMed]

Fernández Ruiz M, Parra P, Ruiz Merlo T, López Medrano F, San Juan R, Polanco N, et al. Association between baseline serum hepcidin levels and infection in kidney transplant recipients: Potential role for iron overload. Transpl Infect Dis. 2018;20(1) [PubMed]

Fernández Ruiz M, Polanco N, García Santiago A, Muñoz R, Hernández AM, González E, et al. Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study. Transpl Int. 2018;31(8):887-99 [PubMed]

Kumar D, Ferreira VH, Blumberg E, Silveira F, Cordero E, Pérez Romero P, et al. A Five-year prospective multi-center evaluation of influenza infection in transplant recipients. Clin Infect Dis. 2018;67(9):1322-9 [PubMed]

Lalueza A, Sanz Trepiana L, Bermejo N, Yaiza B, Morales Cartagena A, Espinosa M, et al. Risk factors for bacteremia in urinary tract infections attended in the emergency department. Intern Emerg Med. 2018;13(1):41–50 [PubMed]

Lalueza A, Silva CP, Alcalá Galiano A, Arrieta E, Cánovas JM, Calero MR, et al. Presacral and intrathoracic extramedullary hematopoiesis in a patient with β thalassemia minor. Clin Respir J. 2018;12(1):322–6 [PubMed]

López Medrano F, Fernández Ruiz M, Silva JT, Carver PL, van Delden C, Merino E, et al. Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation. Clin Microbiol Infect. 2018;24(2):192–8 [PubMed]

Maestro de la Calle G, Fernández Ruiz M, López Medrano F, Polanco N, González E, San Juan R, et al. Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients? Atherosclerosis. 2018;269:204-10 [PubMed]

Martín Díaz A, Rubio JM, Herrero Martínez JM, Lizasoaín M, Ruiz Giardin JM, Jaqueti J, et al. Study of the diagnostic accuracy of microbiological techniques in the diagnosis of malaria in the immigrant population in Madrid. Malar J. 2018;17(1):314.

Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fernández Ruiz M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24 Suppl 2:S71-82 [PubMed]

Morales Cartagena A, Fernández Ruiz M, Lalueza A, Lora Tamayo J, San Juan R, López Medrano F, et al. Impact on mortality of adherence to evidence-based interventions in patients with catheter-related bloodstream infection due to methicillin-sensitive Staphylococcus aureus. Infect Dis (Lond). 2018;50(11-12):837-46

Muñoz P, Vena A, Machado M, Gioia F, Martínez Jiménez MC, Gómez E, et al. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. J Antimicrob Chemother. 2018;73(suppl_4):iv6–12 [PubMed]

Muñoz P, Vena A, Machado M, Martínez Jiménez MC, Gioia F, Gómez E, et al. T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study. J Antimicrob Chemother. 2018;73(suppl_4):iv13–9 [PubMed]

Origüen J, Corbella L, Orellana MA, Fernández Ruiz M, López Medrano F, San Juan R, et al. Comparison of the clinical course of Clostridium difficile infection in glutamate dehydrogenase-positive toxin-negative patients diagnosed by PCR to those with a positive toxin test. Clin Microbiol Infect. 2018;24(4):414–21 [PubMed]

Pérez Ayala A, Fradejas I, Rebollo L, Lora Pablos D, Lizasoain M, Herrero Martínez JM. Usefulness of the Architect Chagas® assay as a single test for the diagnosis of chronic Chagas disease. Trop Med Int Health. 2018;23(6):634-40 [PubMed]

Pérez Barragán E, Sandino Pérez J, Corbella L, Orellana MA, Fernández Ruiz M. Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series. Rev Esp Quimioter. 2018;31(3):268-73

Pérez Parra S, Álvarez M, Fernandez Caballero JA, Pérez AB, Santos J, Bisbal O, et al. Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain. J Antimicrob Chemother. 2018;73(4):1031–8 [PubMed]

Recio R, Herrero Martínez JM, Lizasoaín M, Oliveira E, Pérez Ayala A. Incidental finding observed on a blood smear. Clin Microbiol Infect. 2018;24(2):145 [PubMed]

Redelman Sidi G, Michielin O, Cervera C, Ribi C, Aguado JM, Fernández Ruiz M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective-immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine 1-phosphate receptor modulators and proteasome inhibitors. Clin Microbiol Infect. 2018;24 Suppl 2:S95-107 [PubMed]

Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24 Suppl 2:S53-70 [PubMed]

Ruiz Ruigómez M, Dueñas C, Hernández C, Vinuesa D, Coronado Álvarez NM, Portillo Tuñón V, et al. Clinical predictors of candidemia in medical non-neutropenic, non-ICU patients. The CaMed score. Int J Clin Pract. 2018;e13275

Sandino Pérez J, Mancilla AM, Pérez Barragán E, Fernández Ruiz M. Chryseobacterium bacteraemia: a single-centre case series. Infect Dis (Lond). 2018;50(10):775–8

Santoro Lopes G, Subramanian AK, Molina I, Aguado JM, Rabagliatti R, Len O. Tuberculosis recommendations for solid organ transplant recipients and donors. Transplantation. 2018;102(2S Suppl 2):S60–5 [PubMed]

Scheuerman O, Schechner V, Carmeli Y, Gutiérrez Gutiérrez B, Calbo E, Almirante B, et al. Comparison of predictors and mortality between bloodstream infections caused by ESBL-producing escherichia coli and ESBL-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2018;1–8 [PubMed]

Silva JT, Fernández-Ruiz M, Aguado JM. Multidrug-resistant Gram-negative infection in solid organ transplant recipients: implications for outcome and treatment. Curr Opin Infect Dis. 2018;31(6):499-505

Silva JT, Pérez González V, López Medrano F, Alonso Moralejo R, Fernández Ruiz M, San Juan R, et al. Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature. Clin Transplant. 2018;32(2) [PubMed]

Silva JT, Torre Cisneros J, Aguado JM. Aspergilosis invasora en el receptor de trasplante de órgano sólido Rev Iberoam Micol. 2018;35(4):206-209

Tiago Silva J, López-Medrano F, Aguado JM. Highlights in solid transplant infectious diseases 2015-2017. Rev Esp Quimioter. 2018;31 Suppl 1:52-5

Tous Romero F, Navarro Cutillas V, López Medrano F, Rodríguez Peralto JL, Postigo-Llorente C. IgG4-related disease with skin, submaxillary and pulmonary involvement. J Dtsch Dermatol Ges. 2018;16(7):920-2

Tous Romero F, Navarro Cutillas V, López Medrano F, Rodríguez Peralto JL, Postigo Llorente C. IgG4-related disease with skin, submaxillary and pulmonary involvement. J Dtsch Dermatol Ges. 2018l;16(7):920-2  [PubMed]

Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24 Suppl 2:S21-40 [PubMed]

Unidad de VIH

Berenguer J, Gil Martin Á, Jarrin I, Moreno A, Domínguez L, Montes M, et al. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology. 2018;68(1):32-47

Berenguer J, Jarrín I, Pérez Latorre L, Hontañón V, Vivancos MJ, Navarro J, et al. Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant. Open Forum Infect Dis. 2018;5(1):ofx258.

González Baeza A, Dolengevich Segal H, Pérez Valero I, Cabello A, Téllez MJ, Sanz J, et al. Sexualized drug use (Chemsex) is associated with high-risk sexual behaviors and sexually transmitted infections in HIV-positive men who have sex with men: Data from the U-SEX GESIDA 9416 Study. AIDS Patient Care STDS. 2018;32(3):112–8 [PubMed]

Olveira A, Domínguez L, Troya J, Arias A, Pulido F, Ryan P, et al. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. J Viral Hepat. 2018;25(7):818-24 [PubMed]

Pérez Molina JA, Pulido F, Di Giambenedetto S, Ribera E, Moreno S, Zamora J, et al. Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717. J Antimicrob Chemother. 2018;73(11):2927-35.

Pérez Valero I, Pasquau J, Rubio R, Rivero A, Santos J, Sanz J, et al. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. J Antimicrob Chemother. 2018;73(9):2444-51

Ribera E, Martínez Sesmero JM, Sánchez Rubio J, Rubio R, Pasquau J, Poveda JL, et al. Impacto económico asociado a la implementación de las recomendaciones con grado de evidencia A-I del documento de consenso de GeSIDA/PNS (2015) relativas a la optimización del tratamiento antirretroviral en adultos infectados por virus dela inmunodeficiencia humana con carga viral suprimida en España. Enferm Infecc Microbiol Clin. 2018;36(3):157–64 [PubMed]

Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, et al. Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infecc Microbiol Clin. 2018;36(5):268-76.

Sotillo A, Sierra O, Martínez Prats L, Gutiérrez F, Zurita S, Pulido F, et al. Analysis of drug resistance mutations in whole blood DNA from HIV-1 infected patients by single genome and ultradeep sequencing analysis. J Virol Methods. 2018;260:1-5

Troya J, Montejano R, Ryan P, Gómez C, Matarranz M, Cabello A, et al. Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study. PLoS ONE. 2018;13(6):e0198768